Banyan Capital Management Inc. Takes Position in AbbVie Inc. $ABBV

Banyan Capital Management Inc. bought a new position in shares of AbbVie Inc. (NYSE:ABBV) in the third quarter, HoldingsChannel reports. The firm bought 3,119 shares of the company’s stock, valued at approximately $722,000. AbbVie accounts for 0.3% of Banyan Capital Management Inc.’s investment portfolio, making the stock its 21st largest holding.

A number of other hedge funds have also added to or reduced their stakes in ABBV. Conning Inc. boosted its position in shares of AbbVie by 7.1% during the 2nd quarter. Conning Inc. now owns 191,023 shares of the company’s stock valued at $35,458,000 after acquiring an additional 12,690 shares during the last quarter. Diversified Trust Co raised its stake in AbbVie by 23.6% during the third quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock valued at $13,215,000 after purchasing an additional 10,891 shares in the last quarter. Dohj LLC lifted its position in AbbVie by 41.8% during the second quarter. Dohj LLC now owns 4,529 shares of the company’s stock valued at $802,000 after purchasing an additional 1,335 shares during the last quarter. Permanent Capital Management LP bought a new position in AbbVie during the third quarter valued at $720,000. Finally, Railway Pension Investments Ltd increased its holdings in shares of AbbVie by 33.0% in the 3rd quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock worth $197,723,000 after buying an additional 211,800 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Investor enthusiasm around a reported bispecific trial win and management’s renewed R&D pledge — this strengthens AbbVie’s pipeline narrative and long-term growth prospects. Does AbbVie’s Bispecific Trial Win and R&D Pledge Change The Bull Case For AbbVie (ABBV)?
• Positive Sentiment: Retrospective coverage highlighting AbbVie’s strong 2025 performance reinforces confidence in management’s handling of patent cliffs and portfolio transitions. Why AbbVie Stock Trounced the Market in 2025
• Positive Sentiment: Allergan Aesthetics unveiled new clinical and portfolio data that support continued strength in the aesthetics business — a valuable, higher-margin growth pillar for AbbVie. Allergan Aesthetics Unveils New Data Across Facial Injectables
• Positive Sentiment: On-air analyst commentary recommended staying long ABBV, adding short-term buying pressure from retail and institutional viewers. AbbVie, SLB, Amphenol, And More On CNBC’s ‘Final Trades’
• Neutral Sentiment: Coverage of AbbVie’s drug affordability deal notes management is trying to balance price/access commitments with continued R&D and patient-growth plans — reduces regulatory risk but may cap pricing upside. AbbVie Balances Drug Affordability Deal With R&D And Patient Growth Plans
• Neutral Sentiment: Investor note questioning whether recent gains leave ABBV fairly priced based on DCF and price-to-sales signals — flags valuation scrutiny even as shares rally. Is AbbVie (ABBV) Pricing Reflect Its DCF And Price To Sales Signals After Recent Gains
• Neutral Sentiment: AbbVie launched a migraine-focused awareness program (“Love in Mind”) — positive for brand, patient engagement and uptake of migraine therapies but largely a longer-term marketing play. AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine
• Negative Sentiment: Near-term earnings preview from Zacks suggests AbbVie may lack the setup for an earnings beat next week, which could increase volatility if guidance or execution disappoints. AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth

Analysts Set New Price Targets

ABBV has been the subject of a number of analyst reports. Guggenheim increased their price target on shares of AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a report on Monday, October 20th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, January 21st. Berenberg Bank set a $275.00 price objective on shares of AbbVie in a research report on Tuesday, January 20th. Bank of America boosted their target price on AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Finally, Erste Group Bank downgraded shares of AbbVie from a “buy” rating to a “hold” rating in a research note on Tuesday, October 14th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $249.37.

AbbVie Stock Up 0.8%

Shares of NYSE ABBV opened at $220.42 on Friday. The firm has a market cap of $389.56 billion, a P/E ratio of 166.98, a P/E/G ratio of 0.90 and a beta of 0.36. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81. The business’s 50 day moving average price is $224.67 and its 200 day moving average price is $218.02.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. The firm had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.AbbVie’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same period last year, the company earned $3.00 earnings per share. As a group, research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.